Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 361 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Localized Prostate Cancer Clear all
Not yet recruiting Phase 2 Interventional

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

NCT07574541
View directory record Official record
Conditions
Adenocarcinoma, Prostate Cancer, Neoplasms, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type
Interventions
TriAdeno vaccine, N-803
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 2:11 PM EDT
Active, not recruiting Phase 2 Interventional

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

NCT03436654
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Abiraterone Acetate, Prednisone, GnRH agonist/antagonist
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 22, 2026, 2:11 PM EDT
Completed No phase listed Observational

Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting

NCT00717613
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 22, 2026, 2:11 PM EDT
Withdrawn No phase listed Observational

Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS

NCT01766869
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Jul 22, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

NCT02326805
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Jul 22, 2026, 2:11 PM EDT
Active, not recruiting Phase 2 Interventional

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

NCT04114825
View directory record Official record
Conditions
Prostate Cancer Recurrent
Interventions
RV001V, Placebo
Biological · Other
Lead sponsor
RhoVac APS
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Clearwater, Florida • Towson, Maryland • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Jul 22, 2026, 2:11 PM EDT
Withdrawn Phase 2 Interventional

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

NCT02159690
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Cancer
Interventions
Enzalutamide, Abiraterone acetate, Prednisone, Dutasteride, Degarelix
Drug
Lead sponsor
Kenneth Pienta, MD
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Jul 22, 2026, 2:11 PM EDT
Completed Phase 2 Interventional

Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer

NCT00345813
View directory record Official record
Conditions
Prostate Cancer
Interventions
soy isoflavones, soy protein isolate, placebo
Dietary Supplement · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Jul 22, 2026, 2:11 PM EDT
Recruiting No phase listed Observational

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

NCT01961713
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 22, 2026, 2:11 PM EDT
Completed No phase listed Observational

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

NCT03159676
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proton beam
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 22, 2026, 2:11 PM EDT
Recruiting Not applicable Interventional

Addressing Health Literacy With a Tailored Survivorship Care Plan

NCT06674863
View directory record Official record
Conditions
Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Educational Intervention, Interview, Questionnaire Administration, Supportive Care
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Jul 22, 2026, 2:11 PM EDT
Terminated Phase 2 Interventional Results available

Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer

NCT00526591
View directory record Official record
Conditions
Prostate Cancer
Interventions
Everolimus, conventional surgery
Drug · Procedure
Lead sponsor
Jorge A. Garcia, MD
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Jul 22, 2026, 2:11 PM EDT
Recruiting Phase 2 Interventional

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

NCT06014255
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enoblituzumab, Standard of Care
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 22, 2026, 2:11 PM EDT
Terminated Not applicable Interventional

Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial

NCT02024685
View directory record Official record
Conditions
Adenocarcinoma of Prostate, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III
Interventions
Personalized Treatment Recommendations, Standard patient-physician counseling interaction
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Jul 22, 2026, 2:11 PM EDT
Terminated Phase 2 Interventional Results available

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

NCT04030559
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CDK12 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, DNA Damage Response Gene Mutation, DNA Repair Gene Mutation, FANCA Gene Mutation, FANCD2 Gene Mutation, FANCL Gene Mutation, GEN1 Gene Mutation, NBN Gene Mutation, Prostate Carcinoma, RAD51 Gene Mutation, RAD51C Gene Mutation
Interventions
Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy
Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 22, 2026, 2:11 PM EDT
Recruiting No phase listed Observational

PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound

NCT07184970
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 95 Years · Male only
Enrollment
60 participants
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jul 22, 2026, 2:11 PM EDT
Recruiting Early Phase 1 Interventional

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

NCT03861676
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal brachytherapy with PSMA PET imaging, (18F)DCFPyL
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 22, 2026, 2:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer

NCT01982058
View directory record Official record
Conditions
Prostate Cancer, Sexual Dysfunction and Infertility, Sexuality
Interventions
communication intervention, counseling intervention, nutrition intervention, questionnaire administration
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
6
States / cities
New Brunswick, New Jersey • Newark, New Jersey • Whippany, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Jul 22, 2026, 2:11 PM EDT
Not listed Not applicable Interventional

Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Intermediate Risk Prostate Cancer

NCT04656678
View directory record Official record
Conditions
Prostate Cancer, Prostate Disease
Interventions
Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance
Device
Lead sponsor
Northwell Health
Other
Eligibility
45 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Lake Success, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Jul 22, 2026, 2:11 PM EDT
Active, not recruiting Phase 2 Interventional

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

NCT00329043
View directory record Official record
Conditions
Prostate Cancer
Interventions
LHRH Agonist, Sunitinib Malate, Radical Prostatectomy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 2:11 PM EDT
Recruiting Not applicable Interventional

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT07059884
View directory record Official record
Conditions
Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma
Interventions
Exercise Intervention, Telemedicine, Aerobic Exercise Intervention, Accelerometry, Questionnaire Administration, Interview, Electronic Health Record Review
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Dublin, California • Fremont, California • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 2:11 PM EDT
Completed Phase 2 Interventional

Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00005096
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Jul 22, 2026, 2:11 PM EDT
Active, not recruiting Not applicable Interventional

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

NCT06051942
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Localized Prostate Cancer
Interventions
Robotic Waterjet Treatment
Device
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
Up to 80 Years · Male only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
La Mesa, California • Glenview, Illinois • Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 22, 2026, 2:11 PM EDT
Active, not recruiting Phase 3 Interventional

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

NCT04136353
View directory record Official record
Conditions
Prostate Cancer
Interventions
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
Drug · Radiation
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
19
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Burlington, Massachusetts + 15 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 2:11 PM EDT